IP Library Granted Patent US 9,518,264
Granted Patent B2
US 9,518,264 · App. 15/201,061 · Granted Dec 13, 2016

Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,518,264
App. No.
15/201,061
Granted
Dec 13, 2016
Kind
B2
Abstract

The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.

Claims (3)

1. An antisense oligonucleotide against SMAD7 comprising SEQ ID NO: 9 (5′-YGCACXGAGTGXGTGAGZ-3′), wherein X is 5-methyl-2′-deoxycytidine 5′-monophosphate, Y is 2′-deoxyadenosine methylphosphonate, and Z is 2′-deoxycytidine methylphosphonate, or complements thereof.

2. A method of treating ulcerative colitis, comprising administering to a patient in need thereof an effective amount of the antisense oligonucleotide of claim 1 .

3. A method of treating inflammatory bowel disease, comprising administering to a patient in need thereof an effective amount of the antisense oligonucleotide of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2016
From: MONTELEONE, GIOVANNI
To: GIULIANI INTERNATIONAL, LTD.
Reel/Frame 040176/0459 →
CHANGE OF NAME Recorded Oct 31, 2016
From: GIULIANI INTERNATIONAL LIMITED
To: NOGRA PHARMA LIMITED
Reel/Frame 040520/0654 →